## Dispense with Patient Information available at: www.epic-pharma.com/patientinfo/Oseltamivir-Phosphate-for-Oral-Suspension.pdf

# PATIENT INFORMATION Oseltamivir phosphate for Oral Suspension (OH-sel-TAM-i-vir FOS-fate) Rx Only

## What is oseltamivir phosphate for oral suspension?

Oseltamivir phosphate for oral suspension is a prescription medicine used to:

- treat the flu (influenza) in people 2 weeks of age and older who have had flu symptoms for no more than two days.
- prevent the flu in people who are 1 year of age and older.

It is not known if oseltamivir phosphate for oral suspension is:

- effective in people who start treatment after 2 days of developing flu symptoms.
- effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems.
- effective for the treatment or prevention of flu in people who have weakened immune systems (immunocompromised).
- · safe and effective for the treatment of the flu in children less than 2 weeks of age.
- safe and effective in the prevention of the flu in children less than 1 year of age.

Oseltamivir phosphate for oral suspension does not treat or prevent illness that is caused by infections other than the influenza virus.

Oseltamivir phosphate for oral suspension does not prevent bacterial infections that may happen with the flu.

Oseltamivir phosphate for oral suspension is not recommended for people with end-stage renal disease (ESRD) who are not receiving dialysis.

Oseltamivir phosphate for oral suspension does not take the place of receiving a flu vaccination. Talk to your healthcare provider about when you should receive an annual flu vaccination.

## Who should not take oseltamivir phosphate for oral suspension?

Do not take oseltamivir phosphate for oral suspension if you are allergic to oseltamivir phosphate or any of the ingredients in oseltamivir phosphate for oral suspension. See the end of this leaflet for a complete list of ingredients in oseltamivir phosphate for oral suspension.

## What should I tell my healthcare provider before taking oseltamivir phosphate for oral suspension?

## Before you take oseltamivir phosphate for oral suspension, tell your healthcare provider if you:

- · have kidney problems
- have a history of fructose (fruit sugar) intolerance. Oseltamivir phosphate for oral suspension contains sorbitol and may cause stomach
  upset and diarrhea in people who are fructose intolerant.
- · have any other medical conditions
- are pregnant or plan to become pregnant. Available information indicate that oseltamivir phosphate for oral suspension does not increase
  the risk of birth defects.
- are breastfeeding or plan to breastfeed. Oseltamivir phosphate for oral suspension can pass into breast milk in small amounts.

**Tell your healthcare provider about all the medicines you take,** including prescription or over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

# How should I take oseltamivir phosphate for oral suspension?

- Take oseltamivir phosphate for oral suspension exactly as your healthcare provider tells you to.
- Take oseltamivir phosphate for oral suspension with food or without food. There is less chance of stomach upset if you take oseltamivir phosphate for oral suspension with food.
- If you miss a dose of oseltamivir phosphate for oral suspension, take it as soon as you remember. If it is 2 hours or less before your
  next dose, do not take the missed dose. Take your next dose of oseltamivir phosphate for oral suspension at your scheduled time. Do
  not take 2 doses at the same time.

If your healthcare provider or pharmacist has instructed you to take oseltamivir phosphate for oral suspension, read the detailed Instructions for Use at the end of this leaflet. Ask your pharmacist if you have any questions.

# What are the possible side effects of oseltamivir phosphate for oral suspension?

Oseltamivir phosphate for oral suspension may cause serious side effects, including:

• Serious skin and allergic reactions. Oseltamivir phosphate for oral suspension can cause serious skin and allergic reactions. Stop taking oseltamivir phosphate for oral suspension and get medical help right away if you get any of the following symptoms:

o skin rash or hives

o swelling of your face, eyes, lips, tongue, or throat

o your skin blisters and peels o blisters or sores in your mouth

o trouble breathing o chest pain or tightness

o itchina

• Change in behavior. People, especially children, who have the flu, can develop nervous system problems and abnormal behavior that can lead to death. During treatment with oseltamivir phosphate for oral suspension, tell your healthcare provider right away if you or your child have confusion, speech problems, shaky movements, seizures, or start hearing voices or seeing things that are not really there (hallucinations).

The most common side effects of oseltamivir phosphate for oral suspension when used for treatment of the flu include nausea, vomiting and headache.

The most common side effect of oseltamivir phosphate for oral suspension when used for prevention of the flu include nausea, vomiting headache, and pain,

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of oseltamivir phosphate for oral suspension.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

## How should I store oseltamivir phosphate for oral suspension?

- Store oseltamivir phosphate for oral suspension in the refrigerator for up to 17 days between 36°F to 46°F (2°C to 8°C). Do not freeze.
- Store oseltamivir phosphate for oral suspension for up to 10 days at room temperature between 68°F to 77°F (20°C to 25°C).
- Safely throw away any unused oseltamiyir phosphate for oral suspension that is out of date or no longer needed.

Keep oseltamivir phosphate for oral suspension and all medicines out of the reach of children.

## General information about the safe and effective use of oseltamivir phosphate for oral suspension.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use oseltamivir phosphate for oral suspension for a condition for which it was not prescribed. Do not give oseltamivir phosphate for oral suspension to other people, even if they have the same symptoms you have. It may harm them. If you would like more information, talk with your healthcare provider.

You can ask your healthcare provider or pharmacist for information about oseltamivir phosphate for oral suspension that is written for health professionals.

#### What are the ingredients in oseltamivir phosphate for oral suspension?

Active ingredient: oseltamivir phosphate

Oseltamivir phosphate for oral suspension: monosodium citrate, sodium benzoate, saccharin sodium, sorbitol, titanium dioxide, tutti frutti type FLVP, xanthan gum.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Distributed by:

Epic Pharma, LLC Laurelton, NY 11413 Rev. 06-2023-00 0E2995

#### INSTRUCTIONS FOR USE

#### Oseltamivir phosphate for oral suspension

(OH-sel-TAM-i-vir FOS-fate)

Rx Only

## How do I give a dose of oseltamivir phosphate for oral suspension?

- Step 1. Shake the oseltamivir phosphate for oral suspension bottle well before each use.
- Open the bottle by pushing downward on the child resistant bottle cap and twisting it in the direction of the arrow. Step 2.
- Step 3. Measure the oral suspension with an appropriate oral dosing dispenser to be sure you get the correct dose. Contact your pharmacist if you do not have an appropriate oral dosing dispenser. Give the full contents of oral dosing dispenser directly into the mouth.
- Close the bottle with the child-resistant bottle cap after each use.
- Step 6. Rinse oral dosing dispenser under running tap water and allow to air dry after each use.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Rev. 06-2023-00